Chr. Hansen completed the acquisition of UAS Laboratories from Lakeview for $530m.

Chr. Hansen, a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries, completed the acquisition of UAS Laboratories, a private biotechnology company, from Lakeview Equity Partners, a private equity company, for $530m. “With closing of the UAS Labs acquisition, we look forward to building upon the strengths of both companies. We will expand our probiotic offerings from strain to solution, gain access to new customer groups and move into new indication areas whilst staying true to our commitment to science and R&D. We are really excited to welcome the team from UAS Labs to the Chr. Hansen organization and will pursue a ‘best of both’ approach for the integration to create value for customers and shareholders. I am convinced that together we can truly shape the global probiotics market for the future,” Mauricio Graber, Chr. Hansen Chief Executive Officer.